We are Global Leaders & Expanding says Rahul Nachane, MD, NGL Fine-Chem Excl @IBMTVLIVE
Summary
TLDRRahul G, Managing Director of NGL Fine Cam Limited, discusses the company's 43-year journey specializing in APIs for the veterinary pharmaceutical sector. With a focus on farm animals, NGL Fine Cam has carved a niche in the market, exporting to 55 countries and holding significant market share in its top products. The company, recognized in Forbes' Best Under a Billion list, is financially robust with a 15% average EBITDA over the last decade. Rahul highlights the company's high-quality standards, ISO certifications, and European guidelines compliance, emphasizing future growth potential despite current challenges like pricing pressures and competition from China.
Takeaways
- 😀 Rahul G is the Managing Director of NGL Fine-Cam Limited, a company that manufactures APIs (Active Pharmaceutical Ingredients).
- 🏭 NGL Fine-Cam Limited specializes in veterinary pharmaceuticals, focusing on APIs for farm animals like cows, horses, goats, and sheep.
- 🌐 The company's products are exported to 55 countries, with a strong emphasis on the global market, particularly in the top five products where they hold more than 50% market share.
- 🏅 NGL Fine-Cam Limited has been recognized by Forbes as one of Asia's Best Under a Billion companies, featuring in their list in 2015, 2016, and 2021.
- 📈 The company has a robust financial standing, reporting profits of over 15% EBITDA on average for the last 10 years.
- 🔬 NGL Fine-Cam has a dedicated R&D team of about 40 scientists working on new and innovative products.
- 🌟 The company meets high-quality standards, including ISO certifications and European guidelines for pharmaceutical manufacturing.
- 💹 NGL Fine-Cam is planning a significant expansion, investing 200 crores over the next two years, with a focus on entering the US and European markets.
- 📊 The veterinary industry is growing rapidly, with a strong potential for growth in companion animal healthcare as standards of living improve globally.
- 📈 Despite facing competition and pricing challenges, especially from China, the company is optimistic about future growth and opportunities in the animal health sector.
Q & A
What is the primary business of NGL Fine-Cam Limited?
-NGL Fine-Cam Limited is a company that manufactures APIs (Active Pharmaceutical Ingredients). They sell these APIs to other pharmaceutical companies who then make tablets, capsules, and injections.
How long has NGL Fine-Cam Limited been in operation?
-NGL Fine-Cam Limited is close to 43 years old and has been an API company throughout its journey.
What was the initial focus of NGL Fine-Cam Limited when it started?
-Initially, NGL Fine-Cam Limited focused on making human pharmaceuticals, but for the last 27-28 years, they have specialized mainly in Veterinary Pharmaceuticals.
What types of animals does NGL Fine-Cam Limited primarily serve with their products?
-NGL Fine-Cam Limited primarily serves farm animals such as cows, horses, goats, and sheep with their range of products.
How many different APIs does NGL Fine-Cam Limited produce today?
-NGL Fine-Cam Limited makes almost about 30 different APIs today, with close to 28 of them being for animal or veterinary use, and two for human use.
What makes NGL Fine-Cam Limited unique in the Indian pharmaceutical industry?
-NGL Fine-Cam Limited is unique because it is one of the few companies in India that is focused exclusively on Animal Health, which is more popular across the world.
Has NGL Fine-Cam Limited been recognized for its performance?
-Yes, NGL Fine-Cam Limited has been listed in Forbes' 'Best Under a Billion' in Asia's best billion companies in 2015, 2016, and 2021, which is a major achievement.
What is the export to local sale ratio for NGL Fine-Cam Limited?
-The export to local sale ratio for NGL Fine-Cam Limited is close to 3 to 1, meaning almost 75% of what they produce is exported.
How many countries does NGL Fine-Cam Limited export to?
-NGL Fine-Cam Limited exports its products to almost 55 countries across the world.
What are the top five products in which NGL Fine-Cam Limited is a global leader?
-The script does not specify the exact names of the top five products, but it mentions that NGL Fine-Cam Limited holds more than 50% market share in those products on a global scale.
What quality certifications does NGL Fine-Cam Limited have?
-NGL Fine-Cam Limited has ISO certification 9,1 for Quality, 14,1, and 45,000 for health and safety, and they also meet the European guidelines for pharmaceutical manufacturing known as the IC guidelines.
What is the financial strength of NGL Fine-Cam Limited?
-NGL Fine-Cam Limited has been reporting profits of over 15% EBITDA on average for the last 10 years, indicating that they are financially strong.
What are the company's expansion plans?
-NGL Fine-Cam Limited plans to invest close to 200 crores over the next 2 years to expand their capacity, with 160 crores going into a green field venture to cater to the US and European markets, and another 40 crores to expand capacity in existing markets.
Outlines
💊 Introduction to NGL Fine Cam Limited and Its Specialization
Rahul G, the Managing Director of NGL Fine Cam Limited, introduces his company, which has been in operation for approximately 43 years. The company specializes in manufacturing APIs (Active Pharmaceutical Ingredients) for both human and veterinary pharmaceuticals, with a significant focus on the latter for the past 27-28 years. The business model is B2B, selling APIs to other pharmaceutical companies for the production of tablets, capsules, and injections. NGL Fine Cam Limited is recognized for its specialization in animal health, particularly for farm animals, and is one of the few companies in India to focus exclusively on this niche. The company has a diverse product range, with 28 out of 30 APIs designed for veterinary use. Rahul highlights the company's inclusion in Forbes' list of Asia's best under a billion companies, reflecting its profitability and growth. The company's export-oriented strategy is emphasized, with 75% of production being exported to 55 countries, serving over 400 customers globally.
🌍 Global Market Share and Expansion Plans
Rahul G discusses NGL Fine Cam Limited's position in the global market, particularly in the veterinary industry, where the company competes effectively against China, holding more than 50% market share in its top five products. The industry is experiencing rapid growth, with a significant opportunity in the companion animal segment. Despite facing challenges such as global competition and pricing pressures, the company maintains a strong quality standard, with ISO certifications and adherence to European guidelines for pharmaceutical manufacturing. The company has not faced any product rejection in the last 20 years, a testament to its high-quality standards. Rahul also mentions the company's financial strength, with a consistent profit margin of over 15% EBITDA for the past decade. The company is embarking on a significant expansion plan, investing 200 crores over the next two years, which includes setting up a new plant to cater to the US and European markets. The future potential for the company is considered huge, with a largely untapped market and ample room for growth.
🌐 Veterinary Market Potential and Future Outlook
In the final paragraph, Rahul G addresses the potential of the veterinary market globally, noting that there is significant room for growth, especially in regions like Latin America and Africa where the penetration of veterinary products is currently low. He suggests that as living standards improve in these areas, the demand for animal medicines will increase. The conversation concludes with Rahul expressing optimism about the company's future and inviting investors to consider NGL Fine Cam Limited as a standout company with strong operations and a promising growth story.
Mindmap
Keywords
💡API
💡Veterinary Pharmaceuticals
💡B2B Business
💡Export-Oriented
💡Market Leaders
💡ISO Certification
💡European Guidelines (GMP)
💡R&D Team
💡Profitability
💡Expansion Plans
💡Global Competition
Highlights
Introduction of Rahul G, Managing Director for NGL Fine-Cam Limited.
NGL Fine Limited specializes in manufacturing APIs for the pharmaceutical industry, focusing on Veterinary Pharmaceuticals.
The company has been in operation for approximately 43 years, with a specialization in veterinary APIs for the last 27-28 years.
NGL Fine Cam's products are used for treating farm animals such as cows, horses, goats, and sheep.
The company produces around 30 different APIs, with 28 dedicated to animal use and two for human use.
NGL Fine Cam is recognized as one of the few companies in India focused exclusively on Animal Health.
The company has been listed in Forbes' 'Best Under a Billion' for Asia in 2015, 2016, and 2021.
NGL Fine Cam has a strong export focus, with approximately 75% of production being exported to 55 countries.
The company holds a leadership position in its top five products, with over 50% global market share in terms of volume.
The veterinary industry is growing rapidly, with a strong focus on both farm and companion animals.
NGL Fine Cam meets high-quality standards, including ISO certifications and European guidelines for pharmaceutical manufacturing.
The company has not faced any product rejection in the last 20 years, reflecting its commitment to quality.
NGL Fine Cam has a robust R&D team of around 40 scientists working on new and existing products.
The company has reported profits of over 15% EBITDA on average for the last 10 years.
NGL Fine Cam is planning a significant expansion, investing 200 crores over the next two years to increase capacity.
The company is optimistic about future growth, despite current pricing challenges and competition from China.
The veterinary market has significant untapped potential, especially as standards of living improve globally.
Transcripts
hello everyone we are today with uh
Rahul G he is managing director for NGL
fine cam limited how are you sir I am
very well thank you for this opportunity
which you are giving me yeah pleasure is
all mine sir okay sir please take us
through your success Journey
yeah so I'm I'm uh happy to introduce my
company to you uh NGL fine limited is uh
my company which manufactures uh apis
active pharmaceutical
ingredients um so broadly the Pharma
sector is divided into two parts one is
what we call as the API industry and the
second is the industry which makes the
finished dosages so everybody is aware
of the finished dosages because those
are the tablets capsules which are
bought uh and consumed by people but the
basic drug which goes into making the
tablets and capsules is made by
companies like ours and we sell it to
other Pharma companies who make the
tablet capsule
injection so this is a B2B business
essentially at the
background uh NGL fine cam today is uh
close to about uh 43 years
old um it's been a API company all
throughout its Journey initially when we
started we used to make human
Pharmaceuticals but for the last about
27 28 years we are specialized mainly on
Veterinary Pharmaceuticals so our Focus
has been on making products for the um
Veterinary industry animals
essentially and uh in that our focus is
more on farm animals so cows horses goat
sheep you know those kind of
animals so we make a range of products
which are used uh uh for treating uh
these animals and uh these are
essentially in the range of things like
ders um
uh feed supplements phosphorus
supplements anti Protools which you know
for treating blood diseases so different
segments we make almost about 30
different API today of which uh close to
about 28 are for animal use uh for
veterinary use and two are for uh human
use uh our company is one of the unique
companies here in India there are not
many companies which are focused
exclusively on Animal Health there are
very few companies in that space here in
India though it's more popular across
the world where you find that you know
companies are doing exclusively Animal
Health um in India most of the Pharma
companies do animal health as well as
human health so they are a combination
uh
company so we stand out because we are
very focused on Animal
Health uh our company has also been
mentioned uh in the fobes uh list so
fobes publishes what they call as a best
under billion Asia's best billion
companies where they go through close to
something like 20,000 listed companies
in
Asia so we are talking about China
Pakistan India Bangladesh
Vietnam uh
Malaysia uh Indonesia all of uh it
covers the entire Asia they go through
that and then based on the profitability
and the growth story of that company
they come with a
listing so we have been listed under the
F's uh best and billion in 2015 in 2016
and in 2021 so we have figured in that
list three times which is a uh major uh
achievement for
us um in terms of our uh growth story or
our sales we are
um uh very focused on
export
so our export to local sale is close to
about 3 to 1 so almost 75% of what we
produce we export and today we are
exporting our products to almost about
55 countries across the world we have
over to 400
customers and uh our product is now well
accepted and well regarded all over the
all over the
world and we also
are leaders in our top five products and
when I say leaders I mean on a global
scale we compete against China also and
we hold more than 50% market share in
those products in terms of
volume uh the veterinary industry is
growing uh at a very rapid Pace right
now um it's broadly divided into what
they call as farm animals and companion
animals companion animals mean you know
the pets which we have at home dogs cats
and farm animal means the car C and
horses and camels which are used in
farms and the growth is very strong
right now in the companion animal
space so the future opportunities in
this industry are large and uh uh
there's a lot of scope which is uh yet
to be
explored
um at the same time it also gives rise
to challenges which we face because we
are competing on a global basis China is
a big compet
competitor but
um we are currently in a space where we
can we can compete with China very
comfortably we are very cost competitive
when it comes to our products and uh our
product is well accepted uh across the
world we manufacture to the highest uh
quality standards so uh we have ISO
certification 9,1 for Quality uh 14,1
and 45,000 for health and safety we also
meet what is known as the European
guidelines uh uh for pharmaceutical
manufacturing they are called as the IC
guidelines so we meet the European
guidelines also in all all our
plants so we have very high standards in
our uh quality standards and we are one
of those few companies where we can
proudly say that we have not faced any
product rejection in the last 20 years
so that's the level of uh quality which
we uh
meet we have a full fledged R&D team uh
in our company we have a team of close
to about 40 scientists who work on uh on
new products and innovating existing
products uh we have a very strong team
in terms of uh quality in terms of
marketing in terms of uh placing our
products the company has been uh
reporting profits of over 15% Eva or an
average for the last uh 10 years uh we
are fairly financially strong we have
just embarked now on a big expansion
where we plan to invest close to about
200 crores over the next 2 years uh to
expand our
capacity uh 160 crores is going to go
into a green field Venture where we are
setting up a plant to cater to the US
and uh European markets another 40 cror
will be invested to expand our capacity
uh uh in our uh existing uh Market
markets
uh the future potential for the company
is huge because the market is uh largely
untapped we operate more in you know
small sections where uh we are making uh
products for uh the animal indust
industry it's not as big of Market let's
say as like the human industry but
there's still amples room for growth and
we are very optimistic about how the
things are going to face out in the
future uh we believe uh strongly in our
uh growth story and in our internal
strength and uh uh we encourage you also
to look at uh our company and uh uh I'm
sure you'll find that we are um one of
those standout companies which are which
have got very strong uh
operations okay so what message you
would like to give to the
investors well um as I said meaning it's
a strong uh story for us right
now uh the future growth is uh wide open
currently postco we are facing Chen in
terms of pricing uh and especially very
strong competition from China but I very
optimistic about the future and I think
uh major successes are yet to come okay
so please tell us about your industry
globally uh the veterinary Market
industry is uh quite strong um uh we
need to understand the penetration of in
the markets is not very uh big currently
uh so there are a lot of countries let's
say in Latin America in Africa where
people are poor and they are not able to
afford medicines for themselves so when
they can't afford it for themselves how
can they do it for their animals so
penetration is still low there is huge
potential as the standard of living
starts going up and there is ample room
for growth anything else you would like
to
add no I have covered more or less uh
all the aspects which I would have like
to speak about okay thank you Rahul G
for your uh precious time and
information given to us thank you very
much for the opportunity
Weitere ähnliche Videos ansehen
Hyundai's electric car sales in 2024 have been a disaster
Borr Drilling BORR Q4 2023 Earnings Presentation
Detailed Analysis of Anupam Rasayan 🧪 | High Growth Specialty Chemicals Stock
M&M के कैसे रहे Q1 Result, कंपनी के Group CFO Amarjyoti Barua से जानिए आगे का Growth Outlook
Stanley Lifestyles IPO | क्या है कंपनी का Price Band? आईपीओ पर विस्तार से जानें कंपनी के MD से IPO
【精华版】|Fibromat Berhad | 如何从经济金融危机变为转机 | 公司收入因为马来西亚预算案即将迎来增长?!?! | 【乐学成长空间 - LXInvest】
5.0 / 5 (0 votes)